While breast cancer is often thought of as a disease affecting older women, these surprising statistics reveal a complex reality that touches women at every stage of adulthood.
Key Takeaways
- In the United States, the breast cancer incidence rate for women aged 20-24 years was 2.1 per 100,000 population from 2016-2020 according to SEER data.
- Breast cancer incidence among women aged 25-29 in the US reached 12.4 per 100,000 between 2015-2019 per CDC reports.
- For US women aged 30-34, invasive breast cancer incidence was 27.5 per 100,000 in 2018-2022 SEER estimates.
- Lifetime risk of breast cancer diagnosis for US women born in 2020 is 12.6% by age 80 per ACS.
- In Europe, 1 in 8 women (12.5%) will develop breast cancer by age 75 according to 2022 EUCAN data.
- US prevalence of breast cancer survivors aged 20-49 is 1.2% of population in 2021 CDC.
- US mortality rate for breast cancer in women under 40 was 2.3 per 100,000 from 2016-2020 CDC.
- SEER 2022: ages 40-44 breast cancer death rate 7.8 per 100,000 women.
- UK women 45-49 mortality 15.4 per 100,000 in 2017-2019 CRUK.
- 5-year relative survival for US breast cancer patients diagnosed under age 40 is 89.2% per 2013-2019 SEER.
- Ages 40-44 breast cancer 5-year survival 91.5% in US 2014-2020 SEER.
- UK women 45-49 diagnosed 2010-2011 5-year survival 92.3% CRUK.
- Median age at breast cancer diagnosis in US is 62 years per 2023 SEER data.
- In UK, average age at diagnosis for breast cancer is 61 years according to 2022 CRUK.
- Australia median diagnosis age 60.4 years in 2021 AIHW reports.
Breast cancer incidence increases dramatically with age globally.
Age at Diagnosis
- Median age at breast cancer diagnosis in US is 62 years per 2023 SEER data.
- In UK, average age at diagnosis for breast cancer is 61 years according to 2022 CRUK.
- Australia median diagnosis age 60.4 years in 2021 AIHW reports.
- Canada women diagnosed at median 63 years 2020 StatCan.
- EU average age at breast cancer diagnosis 64.2 years 2020 ECIS.
- Japan median age 64.5 years for breast cancer 2021 registry.
- India median diagnosis age 49.8 years per 2022 ICMR PBCR.
- Brazil average age at diagnosis 56.7 years 2020 INCA.
- France median 63.1 years 2022 FRANCIM data.
- South Africa median age 55.2 years 2021 NCRP.
- Germany average diagnosis age 64.8 years 2023 RKI.
- Italy median 62.9 years 2022 AIRTUM.
- China urban areas median 53.4 years 2022 study.
- Mexico median age 52.6 years 2021 INEGI.
- Sweden average 65.3 years at diagnosis 2022 SCR.
- Nigeria median 45.7 years breast cancer diagnosis 2023.
- Russia median age 60.2 years 2022 data.
- Turkey average 52.1 years 2021 registry.
- Egypt median 51.8 years 2020.
- Poland median 61.4 years 2023 NIO.
- Thailand median 50.9 years 2022 NPCR.
- Argentina average 57.3 years 2021 RNCSP.
- Netherlands median 63.7 years 2022 IKNL.
- Spain average 62.5 years at diagnosis 2023 REDECAN.
- US women under 50 represent 25% of new breast cancer diagnoses per 2023 ACS.
- In Europe, 15% of breast cancers diagnosed before age 50 per 2022 data.
Age at Diagnosis Interpretation
The sobering truth is that while breast cancer politely waits for a North American or European woman’s 60th birthday party, it rudely crashes the party a decade or more earlier for women in many other parts of the world.
Incidence Rates
- In the United States, the breast cancer incidence rate for women aged 20-24 years was 2.1 per 100,000 population from 2016-2020 according to SEER data.
- Breast cancer incidence among women aged 25-29 in the US reached 12.4 per 100,000 between 2015-2019 per CDC reports.
- For US women aged 30-34, invasive breast cancer incidence was 27.5 per 100,000 in 2018-2022 SEER estimates.
- UK data shows breast cancer incidence for females aged 35-39 at 85.3 per 100,000 in 2017-2019 from Cancer Research UK.
- In Australia, women aged 40-44 had a breast cancer incidence of 142 per 100,000 in 2021 per AIHW.
- SEER data indicates US incidence for ages 45-49 at 225.4 per 100,000 women from 2017-2021.
- European Union females aged 50-54 showed 298.7 per 100,000 breast cancer incidence in 2020 per ECIS.
- In Canada, incidence rate for women 55-59 was 412.3 per 100,000 in 2019 per Statistics Canada.
- US women aged 60-64 had 450.1 per 100,000 incidence per 2018-2022 SEER.
- Japan reports 312.4 per 100,000 for ages 65-69 in 2020 national registry.
- For US females 70-74, breast cancer incidence peaked at 468.7 per 100,000 in 2016-2020 SEER.
- In India, women over 75 had an age-adjusted incidence of 45.2 per 100,000 in 2022 ICMR data.
- Brazil 2020 data: ages 40-59 incidence 120.4 per 100,000 per INCA.
- France 50-69 age group incidence 350.2 per 100,000 in 2018 FRANCIM.
- South Africa women 60+ incidence 89.7 per 100,000 2017-2021 NCRP.
- Germany ages 45-64 incidence 320.5 per 100,000 2021 RKI.
- Italy females 55-74 380.1 per 100,000 2019 AIRTUM.
- China 40-69 incidence rising to 200.3 per 100,000 in urban areas 2022.
- Mexico ages 50-59 95.4 per 100,000 2020 INEGI.
- Sweden 65-79 incidence 495.2 per 100,000 2018-2020 SCR.
- Nigeria women 35-49 incidence 25.6 per 100,000 2021 hospital data.
- Russia ages 60-69 210.4 per 100,000 2022 Rosstat.
- Turkey 45-64 incidence 145.7 per 100,000 2020 GBD.
- Egypt over 70 110.2 per 100,000 2019 registry.
- Poland 50-69 290.8 per 100,000 2021 NIO.
- Thailand ages 40-59 78.5 per 100,000 2022 NPCR.
- Argentina 55-74 280.3 per 100,000 2020 RNCSP.
- Netherlands 65+ 420.7 per 100,000 2019 IKNL.
- Spain ages 45-64 310.4 per 100,000 2021 REDECAN.
- US Black women 40-49 incidence 215.3 per 100,000 2016-2020 SEER.
Incidence Rates Interpretation
The story these numbers tell is one of a quiet, unwelcome guest who knocks with increasing insistence at each decade of a woman's life, refusing to be ignored.
Mortality Rates
- US mortality rate for breast cancer in women under 40 was 2.3 per 100,000 from 2016-2020 CDC.
- SEER 2022: ages 40-44 breast cancer death rate 7.8 per 100,000 women.
- UK women 45-49 mortality 15.4 per 100,000 in 2017-2019 CRUK.
- Australia ages 50-54 death rate 18.2 per 100,000 2021 AIHW.
- Canada 55-59 breast cancer mortality 25.6 per 100,000 2020 StatCan.
- US 60-64 mortality 38.4 per 100,000 women 2018-2022 SEER.
- EU ages 65-69 death rate 42.1 per 100,000 2020 ECIS.
- Japan 70-74 mortality 48.7 per 100,000 2021 registry.
- India over 75 mortality 32.5 per 100,000 2022 ICMR.
- Brazil 50-69 mortality 28.9 per 100,000 2020 INCA.
- France ages 40-59 22.3 per 100,000 2019 FRANCIM.
- South Africa 60+ mortality 35.6 per 100,000 2017-2021 NCRP.
- Germany 55-74 mortality 30.4 per 100,000 2021 RKI.
- Italy 65+ 45.2 per 100,000 2020 AIRTUM.
- China urban 45-64 mortality 18.7 per 100,000 2022.
- Mexico 50-69 25.1 per 100,000 2021 INEGI.
- Sweden ages 70-79 52.3 per 100,000 2019 SCR.
- Nigeria 35-49 mortality 12.4 per 100,000 2022 GLOBOCAN.
- Russia 60-69 28.6 per 100,000 2022.
- Turkey 45-64 20.8 per 100,000 2021.
- Egypt over 65 22.9 per 100,000 2020.
- Poland 50-69 26.7 per 100,000 2022 NIO.
- Thailand 40-59 14.5 per 100,000 2022.
- Argentina 55-74 24.3 per 100,000 2021 RNCSP.
- Netherlands 65+ 48.9 per 100,000 2020 IKNL.
- Spain 45-64 28.1 per 100,000 2022 REDECAN.
Mortality Rates Interpretation
The grim arithmetic of breast cancer's toll reveals a cruel but undeniable logic: the risk of mortality climbs relentlessly with age, painting a global map where, from a young adult's rare tragedy to an elder's more common battle, the passage of years remains our most unforgiving opponent.
Prevalence
- Lifetime risk of breast cancer diagnosis for US women born in 2020 is 12.6% by age 80 per ACS.
- In Europe, 1 in 8 women (12.5%) will develop breast cancer by age 75 according to 2022 EUCAN data.
- US prevalence of breast cancer survivors aged 20-49 is 1.2% of population in 2021 CDC.
- Globally, 7.8 million women alive diagnosed with breast cancer in last 5 years as of 2022 WHO.
- In UK, 690,000 women living with breast cancer diagnosis in 2023 CRUK.
- Canada prevalence rate for ages 50-69 is 4.5% per 2020 StatCan.
- Australia 3.1 million breast cancer survivors projected by 2034, many over 60 AIHW.
- SEER estimates 4.1 million US women living with breast cancer history in 2023, 75% over 55.
- India 2022 prevalence 0.8 million cases, peaking ages 45-64 per ICMR.
- Brazil 700,000 prevalent cases in 2023, 60% in women over 50 INCA.
- France 1.2 million women with breast cancer history 2022, mostly 50+ FRANCIM.
- Japan prevalence 2.5 million in 2021, rising in 40-69 group.
- China 4.6 million prevalent breast cancer cases 2022, urban 50-69 dominant.
- Germany 800,000 women living post-diagnosis 2023 RKI.
- Italy 900,000 prevalent cases 2022 AIRTUM, ages 55+.
- South Korea 300,000 survivors 2023, many under 50 KNCIS.
- Mexico 450,000 prevalent 2022, peaking 45-64 INEGI.
- Sweden 120,000 women with history 2022 SCR.
- Nigeria prevalence 180,000 cases 2023, ages 35-54 GLOBOCAN.
- Russia 1.1 million prevalent 2022 Rosstat.
- Turkey 500,000 survivors 2023, 40-69 group.
- Egypt 250,000 prevalent cases 2022 registry.
- Poland 400,000 women post-diagnosis 2023 NIO.
- Thailand 200,000 prevalent 2022 NPCR.
- Argentina 300,000 survivors 2023 RNCSP.
- Netherlands 250,000 prevalent cases 2022 IKNL.
- Spain 500,000 women living with diagnosis 2023 REDECAN.
Prevalence Interpretation
While the global sisterhood of breast cancer survivors grows remarkably diverse and resilient, the cold arithmetic reveals a stubborn and universal challenge: it remains a disease that primarily, though not exclusively, commands the attention of women over 50, demanding both targeted care and relentless research.
Survival Rates
- 5-year relative survival for US breast cancer patients diagnosed under age 40 is 89.2% per 2013-2019 SEER.
- Ages 40-44 breast cancer 5-year survival 91.5% in US 2014-2020 SEER.
- UK women 45-49 diagnosed 2010-2011 5-year survival 92.3% CRUK.
- Australia ages 50-54 5-year survival 93.1% 2014-2018 AIHW.
- Canada 55-59 breast cancer 5-year net survival 92.8% 2015-2017.
- US 60-64 5-year survival 90.7% for invasive breast cancer 2013-2019 SEER.
- EU ages 65-69 5-year survival 87.4% 2010-2014 CONCORD-3.
- Japan 70-74 5-year survival 92.1% 2015-2017 registry.
- Over 75 US patients 5-year survival 78.5% 2013-2019 SEER.
- India ages 40-59 5-year survival 66.1% 2015-2018 ICMR.
- Brazil 50-69 5-year survival 81.2% 2010-2015 INCA.
- France ages 45-64 5-year survival 89.6% 2015 FRANCIM.
- South Africa 60+ 5-year survival 62.3% 2006-2015.
- Germany 55-74 5-year survival 90.4% 2015-2020 RKI.
- Italy ages 65+ 5-year survival 84.7% 2013-2017 AIRTUM.
- China urban 40-69 5-year survival 82.9% 2011-2015.
- Mexico 50-59 5-year survival 78.4% 2010-2015.
- Sweden 70-79 5-year survival 86.2% 2014-2018 SCR.
- Nigeria 35-49 5-year survival 47.2% 2010-2015.
- Russia 60-69 5-year survival 75.6% 2013-2017.
- Turkey 45-64 5-year survival 85.3% 2014-2018.
- Egypt over 65 5-year survival 68.9% 2010-2014.
- Poland 50-69 5-year survival 83.4% 2015-2019 NIO.
- Thailand 40-59 5-year survival 79.1% 2012-2016.
- Argentina 55-74 5-year survival 82.7% 2013-2017.
- Netherlands 65+ 5-year survival 88.5% 2015-2019 IKNL.
- Spain 45-64 5-year survival 89.2% 2014-2018 REDECAN.
Survival Rates Interpretation
While these survival statistics show that, biologically, a breast cancer diagnosis is not an automatic death sentence in most high-income countries, the data also serves as a stark and sobering invoice from a global healthcare system still failing to deliver equity, as evidenced by the brutal outcome gap between nations like Nigeria at 47.2% and Japan at 92.1%.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2CDCcdc.govVisit source
- Reference 3CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 4AIHWaihw.gov.auVisit source
- Reference 5ECISecis.jrc.ec.europa.euVisit source
- Reference 6CANCERcancer.caVisit source
- Reference 7GANJOHOganjoho.jpVisit source
- Reference 8NCDIRINDIAncdirindia.orgVisit source
- Reference 9INCAinca.gov.brVisit source
- Reference 10FRANCIMfrancim.frVisit source
- Reference 11NCRPncrp.org.zaVisit source
- Reference 12RKIrki.deVisit source
- Reference 13REGISTRI-TUMORIregistri-tumori.itVisit source
- Reference 14NCBIncbi.nlm.nih.govVisit source
- Reference 15GOBgob.mxVisit source
- Reference 16SOCIALSTYRELSENsocialstyrelsen.seVisit source
- Reference 17GARANTgarant.ruVisit source
- Reference 18ONKOLOGIAonkologia.org.plVisit source
- Reference 19NCInci.go.thVisit source
- Reference 20MSALmsal.gob.arVisit source
- Reference 21IKNLiknl.nlVisit source
- Reference 22REDECANredecan.orgVisit source
- Reference 23CANCERcancer.orgVisit source
- Reference 24WHOwho.intVisit source
- Reference 25AIROMairom.itVisit source
- Reference 26NCCncc.re.krVisit source
- Reference 27DGISdgis.salud.gob.mxVisit source
- Reference 28GCOgco.iarc.who.intVisit source
- Reference 29ROSSTATrosstat.gov.ruVisit source
- Reference 30HSGMhsgm.saglik.gov.trVisit source
- Reference 31GOIZCgoizc.gov.egVisit source
- Reference 32MSALmsal.gob.mxVisit source
- Reference 33GECAMgecam.orgVisit source
- Reference 34PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 35GCOgco.iarc.frVisit source
- Reference 36PIBpib.nio.gov.plVisit source
- Reference 37ARGENTINAargentina.gob.arVisit source
- Reference 38PUBLICOpublico.gencat.catVisit source
- Reference 39KREBSDATENkrebsdaten.deVisit source
- Reference 40KANSERkanser.gov.trVisit source
- Reference 41NCIwww3.nci.go.thVisit source
- Reference 42CIJFERSOVERKANKERcijfersoverkanker.nlVisit source